MYC and Miyoshi myopathy: The interaction between miRNAs and transcription factors may be susceptible of pharmacologic intervention: a specific LNA gapmeR inhibitor that selectively targets MIR17HG primary transcript, named MIR17PTi, is able to disrupt the MYC/miR-17-92 FFL and to trigger apoptosis by inducing MYC-dependent synthetic lethality in patient-derived MM cells [129].